Table 2.
Relationship between CANT1 Expression and Clinicopathological Data of Primary Prostate Carcinoma Specimens (RPE) in Cohort #2
| n = 640 Median (range)/cases (percentage) | Golgi staining |
|||
|---|---|---|---|---|
| Parameter | CANT1 low | CANT1 high | P value | |
| Age | 62 (43–74) | 0.273 | ||
| ≤62 years | 196 | 116 | ||
| >62 years | 205 | 100 | ||
| Pre-OP PSA | 7.2 (0.8–39) | 0.701 | ||
| ≤10 ng/mL | 293 | 153 | ||
| >10 ng/mL | 104 | 59 | ||
| Gleason score | 0.054 | |||
| 5–6 | 234 (36.6%) | 136 | 84 | |
| 7 | 293 (45.8%) | 185 | 103 | |
| 8–10 | 112 (17.5%) | 80 | 29 | |
| pT status | 0.014⁎ | |||
| pT2 | 442 (69.1%) | 262 | 162 | |
| pT3/4 | 197 (30.8%) | 139 | 54 | |
| Margin status | 0.569 | |||
| R0 | 463 (72.3%) | 287 | 159 | |
| R1 | 173 (27%) | 113 | 55 | |
pre-OP PSA, preoperative prostate-specific antigen; RPE, radical prostatectomy.
⁎
Statistically significant.